EGRX Shares Outstanding History



Below is a table of the EGRX shares outstanding history going back to 2/12/2014:

Date EGRX Shares Outstanding
2/12/201413.90M
5/12/201414.02M
8/8/201414.02M
12/17/201414.03M
2/13/201514.04M
5/11/201515.54M
8/10/201515.59M
11/10/201515.59M
2/10/201615.64M
4/15/201615.64M
5/3/201615.64M
8/4/201615.64M
11/4/201615.44M
3/3/201715.23M
5/3/201715.30M
8/2/201715.17M
11/1/201714.92M
2/20/201814.86M
5/3/201814.84M
7/31/201815.06M
10/25/201814.91M
2/22/201913.92M
4/30/201913.93M
7/31/201913.67M
10/31/201913.67M
2/24/202013.68M
5/4/202013.69M
8/3/202013.61M
10/29/202013.03M
2/25/202113.22M
5/3/202113.11M
8/2/202113.10M
11/2/202112.91M
2/28/202212.70M
4/25/202212.70M
5/3/202212.70M
8/2/202213.28M
11/2/202213.02M
3/16/202313.08M
5/2/202313.09M
8/1/202312.99M

Also see: EGRX Market Cap History
EGRX YTD Return
EGRX Historical Shares Outstanding:
-0.72% CAGR
EGRX Historical Shares Outstanding: +-0.72% CAGR

Mouse over chart for data details
2/12/2014 ...8/1/2023
Eagle Pharmaceuticals is an integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. Co.'s products and product portfolio include: BARHEMSYS® (amisulpride for injection), which is for the treatment of postoperative nausea and vomiting; BYFAVO® (remimazolam for injection), which is indicated for the induction and maintenance of procedural sedation; bendamustine ready-to-dilute (RTD) 500ml solution, infused bendamustine RTD, and bendamustine RTD and infused RTD in Japan for Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma; Ryanodex® (dantrolene sodium) for Malignant Hyperthermia; and EA-114 (fulvestrant) for breast cancer. We show 41 historical shares outstanding datapoints in our coverage of EGRX's shares outstanding history.

Understanding the changing numbers of EGRX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like EGRX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching EGRX by allowing them to research EGRX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree EGRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Eagle Pharmaceuticals (EGRX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

EHAB Shares Outstanding History
EHC Shares Outstanding History
EIDX Shares Outstanding History
EIGR Shares Outstanding History
EKSO Shares Outstanding History
ELAN Shares Outstanding History
ELDN Shares Outstanding History
ELEV Shares Outstanding History
ELGX Shares Outstanding History
ELOX Shares Outstanding History
More Healthcare companies »

 

EGRX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.